Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN · NASDAQ Capital Market
+$0.11 today
Vol 2.64M · Avg 1.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-56.3%
avg -217.2%
ROIC
-55.1%
avg -71.6%
ROA
-27.0%
avg -71.9%
Analysis
ROA is currently the strongest return metric at -27.0% versus its period average of -71.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David-Alexandre C. Gros | Chief Executive Officer & Non Independent Director | $984,408.00 | — | 54 | $600,000.00 | 1.00% |
Steven N. Perrin | President, Chief Scientific Officer & Non Independent Director | $792,156.00 | — | 60 | $27,000.00 | 0.05% |
Paul Sean Little | Chief Financial Officer | $717,378.00 | — | 61 | $175,000.00 | 0.29% |
Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer | $377,136.00 | — | 46 | $64,500.00 | 0.11% |
Eliezer Katz | Chief Medical Officer | — | — | — | — | — |
John Herberger | Vice President of Technical Operations | — | — | — | $0.00 | <0.01% |
David Hovland | Chief Regulatory Officer | — | — | — | $12,000.00 | 0.02% |
Marina Escudero | Vice President & Head of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$502.84M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$488.93M
Puma Biotechnology, Inc.
NASDAQ:PBYI
$376.91M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$349.09M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$346.92M
Abeona Therapeutics Inc.
NASDAQ:ABEO
$325.16M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.86M
Editas Medicine, Inc.
NASDAQ:EDIT
$256.99M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.86M
Humacyte, Inc.
NASDAQ:HUMA
$156.32M
Who manages ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) lists 8 active executives. The top listed executive is Eliezer Katz, Chief Medical Officer.
Are ELDN insiders buying or selling?
Recent insider activity shows net selling of $1.63B.
Explore More
Continue the stock analysis
Jump to another research area for this company.